MD4635C1 - Compuşi de chinolină substituiţi selectiv - Google Patents

Compuşi de chinolină substituiţi selectiv

Info

Publication number
MD4635C1
MD4635C1 MDA20160052A MD20160052A MD4635C1 MD 4635 C1 MD4635 C1 MD 4635C1 MD A20160052 A MDA20160052 A MD A20160052A MD 20160052 A MD20160052 A MD 20160052A MD 4635 C1 MD4635 C1 MD 4635C1
Authority
MD
Moldova
Prior art keywords
selectively substituted
substituted quinoline
quinoline compounds
tlr
sle
Prior art date
Application number
MDA20160052A
Other languages
English (en)
Russian (ru)
Other versions
MD4635B1 (ro
MD20160052A2 (ro
Inventor
Эрик КАРЛСОН
Ханс ХАНСЕН
Мэтью МЭКИ
Шон ШИЛЛЕР
Чикако ОГАВА
Хизер ДЭВИС
Ацуси ЭНДО
Линн ХОУКИНС
Салли ИСИДЗАКА
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of MD20160052A2 publication Critical patent/MD20160052A2/ro
Publication of MD4635B1 publication Critical patent/MD4635B1/ro
Publication of MD4635C1 publication Critical patent/MD4635C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Variantele de realizare a invenţiei se referă la compuşi de chinolină substituiţi selectiv, care acţionează ca antagonişti sau inhibitori ai receptorilor Toll-similari (TLR) 7 şi/sau 8, precum şi la utilizarea lor în compoziţii farmaceutice, eficiente pentru tratamentul lupusului eritematos sistemic (LES) şi nefritei lupice.Secvenţe: 2
MDA20160052A 2013-10-14 2014-10-14 Compuşi de chinolină substituiţi selectiv MD4635C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890718P 2013-10-14 2013-10-14
PCT/US2014/060418 WO2015057659A1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds

Publications (3)

Publication Number Publication Date
MD20160052A2 MD20160052A2 (ro) 2016-09-30
MD4635B1 MD4635B1 (ro) 2019-06-30
MD4635C1 true MD4635C1 (ro) 2020-01-31

Family

ID=51842881

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160052A MD4635C1 (ro) 2013-10-14 2014-10-14 Compuşi de chinolină substituiţi selectiv

Country Status (35)

Country Link
US (5) US9428495B2 (ro)
EP (3) EP3057964B1 (ro)
JP (3) JP6223563B2 (ro)
KR (2) KR101823488B1 (ro)
CN (2) CN110105346B (ro)
AR (1) AR098014A1 (ro)
AU (2) AU2014334554B2 (ro)
BR (1) BR112016008359B1 (ro)
CA (1) CA2927510C (ro)
CL (1) CL2016000662A1 (ro)
CY (1) CY1122776T1 (ro)
DK (1) DK3057964T3 (ro)
ES (1) ES2773303T3 (ro)
HK (1) HK1223092A1 (ro)
HR (1) HRP20200147T1 (ro)
HU (1) HUE048706T2 (ro)
IL (2) IL245131B (ro)
JO (1) JO3554B1 (ro)
LT (1) LT3057964T (ro)
MA (1) MA39034B1 (ro)
MD (1) MD4635C1 (ro)
MX (2) MX364657B (ro)
MY (1) MY192489A (ro)
PE (1) PE20160608A1 (ro)
PH (1) PH12016500642A1 (ro)
PL (1) PL3057964T3 (ro)
PT (1) PT3057964T (ro)
RS (1) RS59911B1 (ro)
RU (1) RU2679622C2 (ro)
SG (3) SG11201602818TA (ro)
SI (1) SI3057964T1 (ro)
TW (2) TWI702218B (ro)
UA (1) UA120039C2 (ro)
WO (1) WO2015057659A1 (ro)
ZA (4) ZA201601882B (ro)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791073A1 (ru) * 2011-12-22 2017-09-29 Мерк Патент Гмбх Новые гетероциклические карбоксамиды в качестве модуляторов активности киназ
EP3057964B1 (en) 2013-10-14 2019-12-04 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
KR102365952B1 (ko) 2013-10-14 2022-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
SI3889145T1 (sl) 2015-12-17 2024-05-31 Merck Patent Gmbh 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
ES2944573T3 (es) * 2016-08-08 2023-06-22 Merck Patent Gmbh Antagonistas de TLR7/8 y usos de los mismos
BR112019004597A2 (pt) * 2016-09-09 2019-06-11 Novartis Ag compostos e composições como inibidores de receptores endossomais do tipo toll
CN109923108B (zh) * 2016-09-09 2022-04-29 百时美施贵宝公司 吡啶基取代的吲哚化合物
SG10201914029RA (en) 2016-10-14 2020-03-30 Precision Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
AU2018302026B2 (en) 2017-07-18 2022-04-07 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
US11130756B2 (en) 2017-08-04 2021-09-28 Bristol-Myers Squibb Company [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
CN117586108A (zh) 2017-10-30 2024-02-23 科罗拉多州立大学董事会法人团体 Toll样受体8（tlr8）特异性拮抗剂及其制备方法和用途
ES2945435T3 (es) 2017-11-14 2023-07-03 Bristol Myers Squibb Co Compuestos de indol sustituidos
EA202091477A1 (ru) 2017-12-15 2020-10-28 Бристол-Маерс Сквибб Компани Замещенные соединения простых индольных эфиров
ES2960411T3 (es) 2017-12-18 2024-03-04 Bristol Myers Squibb Co Compuestos de 4-azaindol
JP7313354B2 (ja) 2017-12-19 2023-07-24 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
EA202091508A1 (ru) 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани 6-азаиндольные соединения
SG11202005696YA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
RU2020123151A (ru) * 2017-12-19 2022-01-20 Мерк Патент Гмбх Антагонисты tlr7/8 и их применение
JP7291707B2 (ja) 2017-12-20 2023-06-15 ブリストル－マイヤーズ スクイブ カンパニー アリールおよびヘテロアリール置換されたインドール化合物
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
MX2020005513A (es) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
WO2019126083A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN108101860B (zh) * 2018-02-08 2021-11-23 苏州敬业医药化工有限公司 顺式-2，6-二甲基吗啉的制备方法
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
JP2021518367A (ja) 2018-03-20 2021-08-02 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Ｉｄｏおよびｔｄｏ調節のための化合物および方法、ならびにそれらのための兆候
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
JP7374130B2 (ja) * 2018-06-05 2023-11-06 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物
WO2019235553A1 (ja) * 2018-06-07 2019-12-12 第一三共株式会社 アゼチジン誘導体及びそのプロドラッグ
CN112313228A (zh) 2018-06-12 2021-02-02 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物
WO2019238629A1 (en) 2018-06-13 2019-12-19 F. Hoffmann-La Roche Ag Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
US11098027B2 (en) * 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11639352B2 (en) 2018-09-04 2023-05-02 Hoffman-La Roche Inc. Benzothiazole compounds for the treatment of autoimmune diseases
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
US20210355122A1 (en) * 2018-09-06 2021-11-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
JP2022501326A (ja) * 2018-09-07 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のための新規ピロリジンアミン化合物
JP2022502480A (ja) * 2018-09-11 2022-01-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのピラゾロピリジンアミン化合物
EP3623369B1 (en) 2018-09-12 2023-10-25 F. Hoffmann-La Roche AG Novel morpholinyl amine compounds for the treatment of autoimmune disease
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物
JP2022505827A (ja) 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール二量体の化合物
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
JP2022506790A (ja) * 2018-11-09 2022-01-17 エフ．ホフマン－ラ ロシュ アーゲー 全身性エリテマトーデスを処置するためのＴＬＲ７～９アンタゴニストとしての、５－［６－［［３－（４，５，６，７－テトラヒドロピラゾロ［４，３－ｃ］ピリジン－１－イル）アゼチジン－１－イル］メチル］モルホリン－４－イル］キノリン－８－カルボニトリル誘導体及び類似化合物
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US20220363665A1 (en) 2019-09-10 2022-11-17 Hoffmann-La Roche Inc. Quinoline compounds for the treatment of autoimmune disease
EP4089083A1 (en) * 2019-09-23 2022-11-16 Accutar Biotechnology Inc. Piperidine-2,6-dione substituted isoindoles in the preparation of substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
BR112022005687A2 (pt) 2019-09-30 2022-06-21 Gilead Sciences Inc Vacinas contra o hbv e métodos para tratar o hbv
US20230219959A1 (en) * 2019-11-19 2023-07-13 Hoffmann-La Roche Inc. Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2021099285A1 (en) * 2019-11-19 2021-05-27 F. Hoffmann-La Roche Ag Triazatricycle compounds for the treatment of autoimmune disease
EP4061821A1 (en) * 2019-11-20 2022-09-28 F. Hoffmann-La Roche AG Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
US20230022297A1 (en) * 2019-12-03 2023-01-26 Hoffmann-La Roche Inc. HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
EP4069729A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4082611A4 (en) * 2019-12-06 2023-12-27 Daiichi Sankyo Company, Limited AZETIDINE SULPHONAMIDE COMPOUND
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
AU2022289728A1 (en) * 2021-06-11 2023-11-16 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
AU2022297373A1 (en) 2021-06-23 2024-01-04 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11999733B2 (en) 2021-06-23 2024-06-04 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TWI849499B (zh) 2021-09-10 2024-07-21 美商基利科學股份有限公司 噻吩并吡咯化合物

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
JPS5890511A (ja) 1981-11-25 1983-05-30 Otsuka Pharmaceut Co Ltd 抗菌剤
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JPH08295690A (ja) 1995-04-26 1996-11-12 Tokuyama Corp クロメン化合物
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
AU4471497A (en) 1996-10-11 1998-05-11 Kowa Co. Ltd. Novel diamide compounds and drugs containing the same
DE19643048A1 (de) 1996-10-18 1998-04-23 Daimler Benz Ag Verbindungen und deren Verwendung sowie Verfahren zur Herstellung von flüssigkristallinen Polymeren daraus
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
YU74701A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati tri-aril kiseline kao ligandi ppar receptora
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
DE19936437A1 (de) 1999-08-03 2001-02-08 Aventis Cropscience Gmbh Kombinationen aus Herbiziden und Safenern
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
HUP0300850A2 (hu) 2000-03-17 2003-07-28 Bristol-Myers Squibb Pharma Company Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE260272T1 (de) 2000-03-17 2004-03-15 Bristol Myers Squibb Pharma Co Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
WO2002018335A1 (fr) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amine cyclique
BRPI0113757B1 (pt) 2000-09-11 2017-05-23 Chiron Corp derivados de quinolinona como inibibores de tirosina quinase
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CN1509184A (zh) 2001-03-19 2004-06-30 �ձ���ҩ��ʽ���� 止痒剂
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
KR20100107509A (ko) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
DE10222166A1 (de) 2002-05-20 2003-12-11 Fraunhofer Ges Forschung Chirale Verbindungen und deren Verwendung
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
JP3908248B2 (ja) 2002-08-13 2007-04-25 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1546109A4 (en) 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
WO2004032846A2 (en) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
GB2396154B (en) 2002-10-15 2007-02-28 Merck Patent Gmbh 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices
US7442475B2 (en) 2003-02-22 2008-10-28 Merck Patent Gmbh Cyanopyridone derivatives as liquid crystals
US8013156B2 (en) 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
JP2006524688A (ja) 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
WO2004087835A1 (en) 2003-04-01 2004-10-14 Merck Patent Gmbh Chiral polymerizable compounds
MXPA05013922A (es) * 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
CN1809357B (zh) * 2003-06-20 2010-12-22 科勒制药有限公司 小分子Toll样受体(TLR)拮抗剂
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
US7211671B2 (en) 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
JP2005132834A (ja) * 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
CN1291977C (zh) * 2003-10-20 2006-12-27 复旦大学 多取代喹啉衍生物功能材料及其制备方法和应用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
KR20060111520A (ko) 2003-11-07 2006-10-27 카이론 코포레이션 Ｆｇｆｒ3의 억제 및 다발성 골수종의 치료
TWI316955B (en) 2003-11-19 2009-11-11 Chisso Corp Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof
CA2555311A1 (en) 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
JP2007523178A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ 代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用
AU2005216904B2 (en) 2004-02-20 2010-11-25 Novartis Vaccines And Diagnostics, Inc. Modulation of inflammatory and metastatic processes
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
WO2005115361A2 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
US20070004679A1 (en) 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
EP1751150A2 (en) 2004-05-19 2007-02-14 Neurosearch A/S Novel azabicyclic aryl derivatives
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006110276A2 (en) 2005-04-08 2006-10-19 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CA2612709C (en) 2005-06-30 2013-10-15 Bionumerik Pharmaceuticals, Inc. Monoimine ligand platinum analogs
JP2007045752A (ja) 2005-08-10 2007-02-22 Takeda Chem Ind Ltd ５員芳香族複素環誘導体、その製造法および用途
JP2007131765A (ja) 2005-11-11 2007-05-31 Fujifilm Corp 液晶性組成物
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
JP2009524637A (ja) 2006-01-27 2009-07-02 ファイザー・プロダクツ・インク アミノフタラジン誘導体化合物
US7989458B2 (en) 2006-07-14 2011-08-02 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US7902363B2 (en) 2006-11-17 2011-03-08 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
AU2008228067B2 (en) * 2007-03-22 2011-12-08 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
US8436028B2 (en) 2007-06-20 2013-05-07 Merck Sharp & Dohme Corp CETP inhibitors derived from benzoxazole arylamides
JP2010530416A (ja) 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
JP5057056B2 (ja) 2007-08-03 2012-10-24 Ｊｓｒ株式会社 液晶配向剤、液晶配向膜の製造方法、ポリアミック酸およびポリイミドならびにジアミン化合物
JP2009108152A (ja) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd 重合性化合物および光学フィルム
CA2703980A1 (en) 2007-10-29 2009-05-07 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors
CN101440062B (zh) 2007-11-23 2011-09-28 齐齐哈尔大学 N-酰基-8-氨基喹啉衍生物的合成及其作为荧光分子探针的应用
JP2009149754A (ja) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd 重合性化合物および該重合性化合物を重合してなる光学フィルム
CA2715842A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoline derivatives
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009137081A2 (en) 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
WO2009139438A1 (ja) 2008-05-15 2009-11-19 田辺三菱製薬株式会社 光学活性カルボン酸の製造方法
AU2009257748A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of FAAH
JP2011524365A (ja) 2008-06-11 2011-09-01 アイアールエム・リミテッド・ライアビリティ・カンパニー マラリアの処置に有用な化合物および組成物
AU2009257795A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of FAAH
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
DK2303021T3 (en) 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
WO2010017079A1 (en) 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah
WO2010018874A1 (en) 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
JP2010066630A (ja) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd 光学フィルムの製造方法及び光学フィルム
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010046445A2 (en) 2008-10-23 2010-04-29 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
WO2010065717A1 (en) 2008-12-05 2010-06-10 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
CN101759683B (zh) 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
EP2398771B1 (en) 2009-02-18 2015-07-29 Boehringer Ingelheim International GmbH Heterocyclic compounds which modulate the cb2 receptor
CN104592219B (zh) 2009-03-16 2017-04-12 住友化学株式会社 化合物、光学膜和光学膜的制造方法
JP5899607B2 (ja) 2009-03-16 2016-04-06 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
JP2011006360A (ja) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
MX2012001419A (es) 2009-08-06 2012-03-16 Merck Patent Gmbh Compuestos biciclicos novedosos de urea.
JP2011042606A (ja) 2009-08-20 2011-03-03 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EP2473491B1 (en) 2009-08-31 2013-07-17 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
KR20120063515A (ko) 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Ｐｉ３ 키나제 억제제 및 이들의 용도
AU2010294292B2 (en) 2009-09-10 2013-07-18 Novartis Ag Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
WO2011068138A1 (ja) 2009-12-01 2011-06-09 住友化学株式会社 シクロアルカンジカルボン酸モノエステルの製造方法
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
JP6017313B2 (ja) 2010-01-13 2016-10-26 テンペロ、ファーマシューティカルズ、インコーポレイテッドＴｅｍｐｅｒｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 化合物および方法
CN102858338A (zh) 2010-01-28 2013-01-02 默沙东公司 治疗疼痛及其它适应症的药物组合物
EA201290774A1 (ru) 2010-02-11 2013-03-29 Вандербилт Юниверсити Пиразолопиридиновые, пиразолопиразиновые, пиразолопиримидиновые, пиразолотиофеновые и пиразолотиазоловые соединения как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011242961B2 (en) 2010-04-22 2015-09-24 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of FAAH
EP2560636A4 (en) 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL COMPOUNDS
EP2977085A1 (en) 2010-04-23 2016-01-27 Kineta, Inc. Diarylpyridine anti-viral compounds
US20120149715A1 (en) 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
JP5652011B2 (ja) 2010-06-10 2015-01-14 住友化学株式会社 光学フィルム
US20130116231A1 (en) 2010-07-12 2013-05-09 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012033390A2 (en) 2010-09-10 2012-03-15 Green Cross Corporation Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012084219A1 (en) 2010-12-23 2012-06-28 Solvay Sa Preparation of a fac-isomer for a tris homoleptic metal complex
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
CN102675289B (zh) 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
TW201311149A (zh) 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
AU2012280725B2 (en) 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013042139A1 (en) 2011-09-23 2013-03-28 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP3057964B1 (en) 2013-10-14 2019-12-04 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
KR102365952B1 (ko) 2013-10-14 2022-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물

Also Published As

Publication number Publication date
SG11201602818TA (en) 2016-05-30
SG10202103278TA (en) 2021-04-29
KR20160068949A (ko) 2016-06-15
EP3995495A1 (en) 2022-05-11
USRE47193E1 (en) 2019-01-08
JP2019023220A (ja) 2019-02-14
CA2927510C (en) 2022-03-01
ZA201608132B (en) 2019-01-30
JP2017226700A (ja) 2017-12-28
AU2014334554B2 (en) 2018-12-06
HUE048706T2 (hu) 2020-08-28
LT3057964T (lt) 2020-02-25
ZA201801112B (en) 2020-10-28
AU2018264036B2 (en) 2020-07-16
IL245131A0 (en) 2016-06-30
BR112016008359B1 (pt) 2022-07-19
RU2016118619A (ru) 2017-11-22
TW201838988A (zh) 2018-11-01
AR098014A1 (es) 2016-04-27
MX364657B (es) 2019-05-03
CN110105346B (zh) 2023-03-10
US20180030045A1 (en) 2018-02-01
UA120039C2 (uk) 2019-09-25
EP3626717A1 (en) 2020-03-25
JP6420878B2 (ja) 2018-11-07
NZ720129A (en) 2021-03-26
IL262970A (en) 2018-12-31
MD4635B1 (ro) 2019-06-30
JP2016535003A (ja) 2016-11-10
RU2679622C2 (ru) 2019-02-12
PT3057964T (pt) 2020-02-25
US9428495B2 (en) 2016-08-30
TWI624467B (zh) 2018-05-21
SG10201704327RA (en) 2017-06-29
JP6223563B2 (ja) 2017-11-01
KR101823488B1 (ko) 2018-01-30
JP6639607B2 (ja) 2020-02-05
MA39034B1 (fr) 2018-09-28
DK3057964T3 (da) 2020-02-24
RS59911B1 (sr) 2020-03-31
US20150105370A1 (en) 2015-04-16
EP3057964A1 (en) 2016-08-24
RU2016118619A3 (ro) 2018-05-23
IL262970B (en) 2019-10-31
MX2016004632A (es) 2016-10-26
HRP20200147T1 (hr) 2020-05-01
TWI702218B (zh) 2020-08-21
JO3554B1 (ar) 2020-07-05
BR112016008359A2 (ro) 2017-10-03
MD20160052A2 (ro) 2016-09-30
PH12016500642B1 (en) 2016-05-30
PE20160608A1 (es) 2016-07-08
CA2927510A1 (en) 2015-04-23
EP3057964B1 (en) 2019-12-04
TW201602100A (zh) 2016-01-16
KR20180011874A (ko) 2018-02-02
CL2016000662A1 (es) 2016-12-16
ZA201601882B (en) 2019-09-25
MA39034A1 (fr) 2018-01-31
CY1122776T1 (el) 2021-05-05
HK1223092A1 (zh) 2017-07-21
WO2015057659A1 (en) 2015-04-23
CN106414432B (zh) 2019-06-14
MX2019005192A (es) 2019-10-21
MY192489A (en) 2022-08-23
IL245131B (en) 2018-11-29
KR102103256B1 (ko) 2020-04-23
ES2773303T3 (es) 2020-07-10
US20160326161A1 (en) 2016-11-10
AU2014334554A1 (en) 2016-06-02
AU2018264036A1 (en) 2018-12-06
CN106414432A (zh) 2017-02-15
US10087174B2 (en) 2018-10-02
ZA201905393B (en) 2020-11-25
SI3057964T1 (sl) 2020-03-31
PL3057964T3 (pl) 2020-05-18
US20180354939A1 (en) 2018-12-13
PH12016500642A1 (en) 2016-05-30
CN110105346A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
MD4635C1 (ro) Compuşi de chinolină substituiţi selectiv
PH12019500522A1 (en) Tetrahydropyrazolopyrimidine compounds
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
IL248347B (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311A0 (en) Compounds and preparations as agonists of toll-like receptor 7
PH12015502141A1 (en) Substituted xanthines and methods of use thereof
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MY179781A (en) Biaryl inhibitors of bruton&#39;s tyrosine kinase
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
NZ763528A (en) Heterocyclic gpr119 agonist compounds
IN2013MU03641A (ro)

Legal Events

Date Code Title Description
FG4A Patent for invention issued